Newsletter November 25, 2019
November 2019: Real World Value: Advancing Payer Understanding of RWE in Rare Disease
Drug developers and regulators are expanding the use of real world evidence to design, test and review rare disease treatments. But market access challenges persist as payers in the U.S. and Europe continue to express doubts. Our new survey sheds light on the perception gap.